Haemonetics Corporation (HAE)
| Market Cap | 4.79B +96.5% |
| Revenue (ttm) | 1.35B +0.4% |
| Net Income | 96.29M -41.1% |
| EPS | 2.06 -37.2% |
| Shares Out | 45.50M |
| PE Ratio | 51.14 |
| Forward PE | 19.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 492,604 |
| Open | 105.72 |
| Previous Close | 106.00 |
| Day's Range | 104.71 - 106.58 |
| 52-Week Range | 47.32 - 110.45 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 111.50 (+5.89%) |
| Est. Earnings | Nov 5, 2026 |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management syst... [Read more]
Financial Performance
In fiscal year 2026, Haemonetics's revenue was $1.33 billion, a decrease of -1.97% compared to the previous year's $1.36 billion. Earnings were $97.31 million, a decrease of -41.97%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $111.5, which is an increase of 5.89% from the latest price.
News
Citi upgrades Haemonetics to Buy on CSL deal upside
Citi upgraded Haemonetics (HAE) to Buy from Neutral with a price target of $123, up from $92. The firm cites potential upside from the company’s non-exclusive supply agreement with CSL…
Haemonetics upgraded to Buy from Neutral at Citi
Citi upgraded Haemonetics (HAE) to Buy from Neutral with a $123 price target
Orchestra BioMed receives $6.1M milestone payment from Haemonetics
Orchestra BioMed (OBIO) announced the receipt of $6.1M as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical by Haemonetics (HAE). This second paym...
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in ad...
Haemonetics price target raised to $125 from $105 at Raymond James
Raymond James analyst Andrew Cooper raised the firm’s price target on Haemonetics (HAE) to $125 from $105 and keeps an Outperform rating on the shares. The recent disclosure of CSL’s…
Haemonetics price target raised to $119 from $96 at Baird
Baird raised the firm’s price target on Haemonetics (HAE) to $119 from $96 and keeps an Outperform rating on the shares.
Haemonetics price target raised to $118 from $95 at Barrington
Barrington raised the firm’s price target on Haemonetics (HAE) to $118 from $95 and keeps an Outperform rating on the shares. The company disclosed a supply agreement under which CSL…
Haemonetics announces supply agreement with CSL Plasma
In a regulatory filing this morning, the company stated: “On August 14, 2026, Haemonetics (HAE) Corporation entered into a supply agreement with CSL Plasma Inc. pursuant to which CSL may…
Haemonetics up 9% at $98.50 in pre-market on CSL Plasma supply agreement
08:34 EDT Haemonetics (HAE) up 9% at $98.50 in pre-market on CSL Plasma supply agreement
Haemonetics price target raised to $120 from $100 at BofA
BofA analyst Travis Steed raised the firm’s price target on Haemonetics (HAE) to $120 from $100 and keeps a Buy rating on the shares. CSL Plastma’s transition of select U.S.
Haemonetics price target raised to $100 from $93 at BofA
BofA raised the firm’s price target on Haemonetics (HAE) to $100 from $93 and keeps a Buy rating on the shares after the firm hosted CEO Chris Simon for a…
Haemonetics price target raised to $105 from $90 at Raymond James
Raymond James raised the firm’s price target on Haemonetics (HAE) to $105 from $90 and keeps an Outperform rating on the shares.
Haemonetics price target raised to $96 from $88 at Baird
Baird raised the firm’s price target on Haemonetics (HAE) to $96 from $88 and keeps an Outperform rating on the shares. The firm updated its model following bigger than expected…
Haemonetics price target raised to $95 from $89 at Barrington
Barrington raised the firm’s price target on Haemonetics (HAE) to $95 from $89 and keeps an Outperform rating on the shares. The firm cites the company’s Q1 beat for the…
Haemonetics price target raised to $92 from $79 at Citi
Citi raised the firm’s price target on Haemonetics (HAE) to $92 from $79 and keeps a Neutral rating on the shares.
Haemonetics Earnings Call Transcript: Q1 2027
Revenue grew 6% year-over-year to $339 million, with all core platforms contributing to profitable growth and adjusted EPS up 4%. FY27 revenue and earnings guidance were raised, supported by strong plasma and MedSurg performance, robust cash flow, and continued innovation momentum.
Haemonetics Slides: Q1 2027
Haemonetics has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 6, 2026.
Haemonetics Earnings release: Q1 2027
Haemonetics released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
Haemonetics Quarterly report: Q1 2027
Haemonetics has published its Q1 2027 quarterly earnings report on August 6, 2026.
Haemonetics reports Q1 adjusted EPS $1.14, consensus $1.08
Reports Q1 revenue $339.38M, consensus $327.89M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies mome...
Haemonetics raises FY27 adjusted EPS view to up 5%-8% from up 4%-7%
Raises FY27 revenue view to up 5%-8% from up 4%-7%.
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal...
Haemonetics’ Vascade MVP system shows efficacy in electrophysiology study
Haemonetics (HAE) announced publication of a study providing new evidence supporting the safety and efficacy of Haemonetics’ Vascade MVP XL venous vascular closure system in large-bore sheath procedur...